Asia-Pacific biotech news最新文献

英文中文

Urine Metabolomics Reveals Overlapping Metabolic Associations Between Preeclampsia and Gestational Diabetes. 尿液代谢组学揭示先兆子痫与妊娠糖尿病之间重叠的代谢关系

IF 1.5

Asia-Pacific biotech news

Pub Date : 2024-07-01 Epub Date: 2022-12-06 DOI: 10.1007/s12291-022-01103-2

Nupur Rani Agarwal, Garima Kachhawa, Bolaji Fatai Oyeyemi, Neel Sarovar Bhavesh

Pregnancy is associated with numerous metabolic adaptations to meet the demands of the growing foetus. These adaptations could be perturbed during pregnancy due to preeclampsia (PE) and gestational diabetes (GDM). As these two obstetric aliments show some overlapping pathophysiology and similar biochemical dysregulation, the present study was undertaken to compare urine metabolome of PE and GDM with normal pregnancy (NT) in all trimesters of gestation using nuclear magnetic resonance spectroscopy-based metabolomics analysis to ascertain and compare metabolome in the study groups. We observed overlapping metabolic perturbations in PE and GDM. Though a study with a small sample size, this is the first report which confirms significantly differential metabolites in urine of both PE and GDM. Dimethylglycine and oxoglutaric acid were decreased while benzoic acid was increased in both the cases in all trimesters. Alanine, aspartate and glutamate metabolism, aminoacyl-tRNA biosynthesis, citrate and butanoate metabolism were the most perturbed pathways in both PE and GDM across pregnancy. These pathways have an association with energy metabolism, glucose homeostasis, insulin sensitivity and oxidative stress which play an important role in the development and progression of PE and GDM. In conclusion, our study showed that urine metabolome could reflect metabolic associations between PE and GDM and also in the identification of biomolecules that could be used as potential biomarker(s) for early detection of the metabolic diseases in pregnancy.

Supplementary information: The online version contains supplementary material available at 10.1007/s12291-022-01103-2.

妊娠与许多新陈代谢适应相关，以满足胎儿成长的需求。在怀孕期间，子痫前期（PE）和妊娠糖尿病（GDM）可能会扰乱这些适应性。由于这两种产科疾病表现出一些重叠的病理生理学和类似的生化失调，本研究采用基于核磁共振波谱的代谢组学分析，对 PE 和 GDM 与正常妊娠（NT）在妊娠期所有三个月的尿液代谢组进行比较，以确定和比较研究组的代谢组。我们在 PE 和 GDM 中观察到了重叠的代谢紊乱。虽然这项研究的样本量较小，但这是第一份证实 PE 和 GDM 尿液中代谢物存在显著差异的报告。在两个病例中，二甲基甘氨酸和氧戊二酸在所有孕期都有所减少，而苯甲酸则有所增加。丙氨酸、天门冬氨酸和谷氨酸代谢、氨基酰-tRNA 生物合成、柠檬酸盐和丁酸盐代谢是 PE 和 GDM 在整个孕期受干扰最大的途径。这些途径与能量代谢、糖稳态、胰岛素敏感性和氧化应激有关，在 PE 和 GDM 的发生和发展中起着重要作用。总之，我们的研究表明，尿液代谢组能反映 PE 和 GDM 之间的代谢关联，还能鉴定出可用作早期检测妊娠期代谢性疾病的潜在生物标记物的生物大分子：在线版本包含补充材料，可在 10.1007/s12291-022-01103-2上查阅。

{"title":"Urine Metabolomics Reveals Overlapping Metabolic Associations Between Preeclampsia and Gestational Diabetes.","authors":"Nupur Rani Agarwal, Garima Kachhawa, Bolaji Fatai Oyeyemi, Neel Sarovar Bhavesh","doi":"10.1007/s12291-022-01103-2","DOIUrl":"10.1007/s12291-022-01103-2","url":null,"abstract":"Pregnancy is associated with numerous metabolic adaptations to meet the demands of the growing foetus. These adaptations could be perturbed during pregnancy due to preeclampsia (PE) and gestational diabetes (GDM). As these two obstetric aliments show some overlapping pathophysiology and similar biochemical dysregulation, the present study was undertaken to compare urine metabolome of PE and GDM with normal pregnancy (NT) in all trimesters of gestation using nuclear magnetic resonance spectroscopy-based metabolomics analysis to ascertain and compare metabolome in the study groups. We observed overlapping metabolic perturbations in PE and GDM. Though a study with a small sample size, this is the first report which confirms significantly differential metabolites in urine of both PE and GDM. Dimethylglycine and oxoglutaric acid were decreased while benzoic acid was increased in both the cases in all trimesters. Alanine, aspartate and glutamate metabolism, aminoacyl-tRNA biosynthesis, citrate and butanoate metabolism were the most perturbed pathways in both PE and GDM across pregnancy. These pathways have an association with energy metabolism, glucose homeostasis, insulin sensitivity and oxidative stress which play an important role in the development and progression of PE and GDM. In conclusion, our study showed that urine metabolome could reflect metabolic associations between PE and GDM and also in the identification of biomolecules that could be used as potential biomarker(s) for early detection of the metabolic diseases in pregnancy.Supplementary information: The online version contains supplementary material available at 10.1007/s12291-022-01103-2.","PeriodicalId":89742,"journal":{"name":"Asia-Pacific biotech news","volume":"10 1","pages":"356-364"},"PeriodicalIF":1.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86395513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pixel Perfect – Imaging Technologies in Biomedical Research (Vol. 27, Nos. 03n04, Full Issue) 像素完美-生物医学研究中的成像技术(第27卷，第03n04号，全期)

Asia-Pacific biotech news

Pub Date : 2023-09-26 DOI: 10.1142/s0219030323000034

In this issue, we have two highlights that will look at how far imaging technologies have come since the X-ray. First, Keefe Chee from BD Life Sciences, Singapore, discusses how real-time imaging spectral flow cytometry (RTI-SFC) allows scientists to identify previously unclassifiable cells in real time, bridging a long-standing gap in biomedical research. And then we have Torrey Smith, CEO of Endiatx, to share with us about PillBot™, the world's first motorised pill camera that will allow a doctor to view the entire stomach and assess for any lesions, making stomach cancer diagnosis more accessible and palatable. Finally, some research highlights we have this issue include a novel diagnostic tool that will improve the clinical diagnosis of neurodegenerative disorders, a textile that can convert body movement into electricity, and a uterine tissue-specific hydrogel that could aid in infertility.

在这一期中，我们有两个重点来看看自x射线以来成像技术的发展。首先，来自新加坡BD生命科学公司的Keefe Chee讨论了实时成像光谱流式细胞术(RTI-SFC)如何使科学家能够实时识别以前无法分类的细胞，从而弥合了生物医学研究中长期存在的空白。接下来，Endiatx的首席执行官Torrey Smith将与我们分享PillBot™。PillBot™是世界上第一款电动药丸相机，它可以让医生看到整个胃，并评估任何病变，使胃癌诊断更容易、更容易接受。最后，我们在这个问题上的一些研究亮点包括一种新的诊断工具，它将改善神经退行性疾病的临床诊断，一种可以将身体运动转化为电的纺织品，以及一种可以帮助治疗不孕症的子宫组织特异性水凝胶。

引用次数: 0

Transforming Healthcare With Technology (Vol. 27, No. 02, Full Issue) 科技变革医疗(27卷02期，全期)

Asia-Pacific biotech news

Pub Date : 2023-06-01 DOI: 10.1142/s0219030323000022

In this issue, APBN looks at the technology that have improved our understanding of the human body and paved the way for future treatments and therapies. First off, we learn about pneumococcal vaccination and how it offers protection against bacterial pneumonia with Dr Chew Huck Chin, respiratory physician and intensivist at Mount Elizabeth Novena Hospital. Then, we hear from Yutaka Shimokawa, Founder and CEO of KINS, about how gut microbes can improve women's hormonal health. In Spotlights, we bring you the highlights from the recent Asia Summit on Global Health as well as an interview with Dr Tan Hong Chang, Senior Consultant at the Singapore General Hospital, and Associate Professor Liu Yu-Chi, Clinician Scientist at the Singapore National Eye Centre, on how a cholesterol drug was repurposed as a new treatment for diabetic corneal neuropathy. In Columns, Dr Jane Leong, Vice President, Medical Affairs Asia Pacific for Moderna, shares how recent developments in mRNA technology could change the way we approach cancer other diseases.

在这一期中，APBN将着眼于提高我们对人体的了解并为未来的治疗和疗法铺平道路的技术。首先，我们与伊丽莎白诺维纳医院呼吸内科医生兼重症监护医师Chew Huck Chin医生一起了解肺炎球菌疫苗接种以及它如何预防细菌性肺炎。然后，我们听取了KINS创始人兼首席执行官Yutaka Shimokawa关于肠道微生物如何改善女性荷尔蒙健康的看法。在重点报道节目中，我们将为您带来最近的亚洲全球健康峰会的亮点，以及对新加坡综合医院高级顾问陈宏章医生和新加坡国家眼科中心临床科学家刘玉琦副教授的采访，探讨一种胆固醇药物如何被重新用作糖尿病角膜神经病变的新治疗方法。在专栏中，Moderna亚太区医疗事务副总裁Jane Leong博士分享了mRNA技术的最新发展如何改变我们治疗癌症和其他疾病的方式。

引用次数: 0

The Future of Cancer Medicine is Precision (Vol. 27, No. 01, Full Issue) 癌症医学的未来是精确的（第27卷第01期，全文）

Asia-Pacific biotech news

Pub Date : 2023-03-01 DOI: 10.1142/s0219030323000010

In this issue, APBN looks into new developments happening within the field of oncology and considers how biotechnology is paving the way for more effective cancer treatments. Firstly, we have Dr Kim Strydom and Dr Edwin Gumafelix of IQVIA to share about CAR-T cell therapy and how we can optimise its clinical trial process to benefit a larger group of patients. Then, Vishal Doshi of AUM Biosciences looks into the potential of biotechnology in transforming cancer therapeutics and how precision medicine can bridge the gaps in cancer care. In Spotlights, we spoke to Dr Lim Hwee Yong, Specialist Medical Oncologist at the Novena Cancer Centre about lung cancer and how the drug Rybrevant presents a hope for patients with a rare type of lung cancer. Finally, in Columns, Dr Varun Sethi of DKSH Business Unit Healthcare describes some of the key trends in Asia-Pacific's healthcare ecosystem and what we can expect to see this year.

在这个问题上，APBN着眼于肿瘤学领域的新发展，并考虑生物技术如何为更有效的癌症治疗铺平道路。首先，我们邀请了IQVIA的Kim Strydom博士和Edwin Gumafelix博士分享CAR-T细胞疗法，以及我们如何优化其临床试验过程，使更多患者受益。然后，AUM Biosciences的Vishal Doshi研究了生物技术在转变癌症治疗方法方面的潜力，以及精准医疗如何弥补癌症治疗方面的差距。在Spotlights，我们采访了Novena癌症中心的肿瘤专家Lim Hwee Yong博士，了解癌症，以及Rybrevant药物如何为罕见类型的癌症患者带来希望。最后，DKSH医疗保健事业部的Varun Sethi博士在专栏中描述了亚太医疗保健生态系统的一些关键趋势，以及我们今年可以看到的情况。

引用次数: 0

Worlds Within Worlds – Viruses, Humanity, and the Environment (Vol. 26, No. 11n12, Full Issue) 世界中的世界-病毒、人类和环境(第26卷，第11n12号，完整版)

Asia-Pacific biotech news

Pub Date : 2022-11-01 DOI: 10.1142/s0219030322000076

For the months of November and December 2022, APBN explores the theme of ''Virology'' and considers the role they play in our environment and how we can deal with them in the years to come. Firstly, we dive into the world of marine viruses with Vanessa Lunardi as she shares with us how these microscopic agents direct life in the ocean and how they could potentially contribute to climate change. Next, Dr Sunny Himansu, Associate Director of Infectious Diseases at Moderna, talks about the Nipah virus, its presence in Southeast Asia, and how Moderna is working to develop a Nipah virus mRNA vaccine. Closer to home, Junghun Justin Kim, Country Manager at Takeda Singapore, discusses the issue of dengue – a disease that has seen a three-fold increase in Singapore this year – and how we can best manage it. Other highlights in this issue include a column by Ivor Campbell, CEO of Snedden Campbell, on the various developments in diagnostics and medical technology as a result of the COVID-19 pandemic, and an interview with Erica Wu Yun, Nurse Clinician at Allium Care Suites on how we can best prepare for a transition from life to death.

在2022年11月和12月，APBN探讨了“病毒学”的主题，并考虑了它们在我们的环境中发挥的作用，以及我们在未来几年如何应对它们。首先，我们与Vanessa Lunardi一起深入海洋病毒的世界，她与我们分享了这些微小的病原体如何指导海洋中的生命，以及它们如何可能导致气候变化。接下来，莫德纳公司传染病副主任Sunny Himansu博士将谈到尼帕病毒，它在东南亚的存在，以及莫德纳公司如何开发尼帕病毒信使核糖核酸疫苗。在离家较近的地方，武田新加坡公司的区域经理Junghun Justin Kim讨论了登革热的问题——今年新加坡的登革热增加了三倍——以及我们如何最好地管理它。本期的其他亮点包括Snedden Campbell首席执行官Ivor Campbell的专栏，关于新冠肺炎大流行导致的诊断和医疗技术的各种发展，以及对Allium Care Suites护士临床医生Erica Wu Yun的采访，了解我们如何为从生到死的过渡做好最佳准备。

引用次数: 0

Toxins and Medicines – Two Sides of the Same Coin (Vol. 26, No. 09n10, Full Issue) 毒素与药物-同一事物的正反两面(第二十六卷，第09n10号，全版)

Asia-Pacific biotech news

Pub Date : 2022-09-01 DOI: 10.1142/s0219030322000064

For the months of September and October 2022, APBN looks at toxins from the natural world and consider its benefits to humanity despite the negative connotation. First up, we have a contribution from Vanessa Lunardi on snake venoms in venom therapy. Then Tara Ng dives into plant secondary metabolites, its properties, and potential applications. While not wholly related to venom therapy, Chang Wei and Dr Mohd Redzwan Sabran from the University of Putra Malaysia, discuss a family of fungal toxins called aflatoxins, its toxic effects, and how probiotics might have aflatoxin-reducing properties. Other highlights in this issue include a column by Dr Chen Min Wei, Consultant Surgeon from the National Neuroscience Institute, and Samuel Choo, Co-Founder and Head of Product at Kyalio, on how immersive virtual reality is bridging the gap between studying and performing surgery, and an interview with Andreas Joergensen, Managing Director of the SEA Cluster at Organon, on women’s healthcare and reproductive health awareness in Asia.

在2022年9月和10月，APBN关注来自自然世界的毒素，并考虑其对人类的好处，尽管其内涵是负面的。首先，我们有Vanessa Lunardi关于毒液治疗中的蛇毒的贡献。然后Tara Ng深入研究了植物次生代谢产物、其特性和潜在应用。马来西亚普特拉大学的Chang Wei和Mohd Redzwan Sabran博士讨论了一种名为黄曲霉毒素的真菌毒素家族、其毒性作用，以及益生菌如何具有减少黄曲霉毒素特性。本期的其他亮点包括国家神经科学研究所外科医生顾问陈敏伟博士和Kyalio联合创始人兼产品主管Samuel Choo的专栏文章，内容是沉浸式虚拟现实如何弥合学习和手术之间的差距，以及对Organon SEA集群总经理Andreas Joergensen的采访，亚洲妇女保健和生殖健康意识。

引用次数: 0

Revolutionising the Reproductive World (Vol. 26, No. 03n04, Full Issue) 《生殖世界的革命》（第26卷，第03n04期，全期）

Asia-Pacific biotech news

Pub Date : 2022-03-01 DOI: 10.1142/s0219030322000039

For the months of March and April 2022, APBN looks at how we can improve and support women's reproductive health. In Features, we have Dr Samuel Prien and Dr Linsay Penrose from Texas Tech University Health Sciences on how we may select the best embryos that will provide the best chances for pregnancy; Dr Alok Javali and Dr Nicolas Rivron from IMBA-Institute of Molecular Biology in Vienna, Austria on how blastoids can be used as a drug discovery tool to improve IVF procedures; and Michelle Tan Min Shuen on reproductive genetic technology. In Columns, Sumir Bhatia, President, Asia Pacific, Lenovo Infrastructure Solutions Group talks about the future of genome sequencing and Justin Loh, Country Director for Singapore, Veritas Technologies tells us how we may protect patient data from data breaches. In Spotlights, we recap the highlights from the Future of Healthcare Week, discussing the path forward in a post-COVID world.

2022年3月和4月，APBN研究如何改善和支持妇女的生殖健康。在Features中，我们有来自德克萨斯理工大学健康科学学院的Samuel Prien博士和Linsay Penrose博士，他们介绍了我们如何选择最有可能怀孕的最佳胚胎；奥地利维也纳IMBA分子生物学研究所的Alok Javali博士和Nicolas Rivron博士介绍了如何将胚细胞用作药物发现工具来改进试管婴儿程序；和Michelle Tan Min-Shuen关于生殖遗传技术。在专栏中，联想基础设施解决方案集团亚太区总裁Sumir Bhatia谈到了基因组测序的未来，Veritas Technologies告诉国家总监Justin Loh告诉我们如何保护患者数据免受数据泄露。在《聚光灯》中，我们回顾了《医疗保健周的未来》的亮点，讨论了后新冠肺炎世界的前进道路。

引用次数: 0

Stronger, Better, Faster – Improving Cancer Treatment and Research (Vol. 26, No. 2, Full Issue) 更强、更好、更快——改善癌症治疗和研究(26卷第2期，全期)

Asia-Pacific biotech news

Pub Date : 2022-01-26 DOI: 10.1142/s0219030322000027

For the month of February 2022, APBN looks at the many ways research is paving the way for improved cancer treatment outcomes. In Features, Kenneth Tan, President of Asia-Pacific, Japan and India at Varian, shares how we can accelerate the path from cancer diagnosis to therapy, improving survivorship. Then, Lance Kawaguchi, CEO of Cure Brain Cancer Foundation, writes about the importance of cancer research, its challenges, and how the Foundation is working to support brain cancer research. For our last feature, we have Dr Ahmed Abdelal, Global Head Medical Affairs Interventional Imaging and North America Head of Medical & Regulatory Affairs, Guerbet and Dr Binta Patel, North America Medical Affairs Manager, Guerbet, to give us a treatment update for hepatocellular carcinoma. Other topics covered in this issue includes the importance of trust in the pharmaceutical industry and how companies can improve trust with technology-led transparency, how we may learn from the pandemic and better prepare for the next unknown crisis, a discussion on the incidence of Omicron and Delta variants in two case studies, and an interview with a spokesperson from Novartis on their newly approved cholesterol drug.

2022年2月，APBN着眼于研究为改善癌症治疗结果铺平道路的多种方式。瓦里安亚太、日本和印度总裁Kenneth Tan在《特写》中分享了我们如何加快从癌症诊断到治疗的道路，提高生存率。然后，治愈脑癌症基金会首席执行官Lance Kawaguchi写下了癌症研究的重要性、面临的挑战，以及该基金会如何支持脑癌症研究。在我们的最后一个专题中，我们邀请了Guerbet全球医疗事务介入成像主管兼北美医疗和监管事务主管Ahmed Abdelal博士和Guerbet北美医疗事务经理Binta Patel博士为我们介绍肝细胞癌的最新治疗情况。本期讨论的其他主题包括信任对制药行业的重要性，以及公司如何通过技术主导的透明度来提高信任，我们如何从疫情中学习并更好地为下一次未知危机做好准备，在两个案例研究中讨论奥密克戎和德尔塔变异株的发病率，以及诺华公司发言人就其新批准的胆固醇药物接受采访。

{"title":"Stronger, Better, Faster – Improving Cancer Treatment and Research (Vol. 26, No. 2, Full Issue)","authors":"","doi":"10.1142/s0219030322000027","DOIUrl":"https://doi.org/10.1142/s0219030322000027","url":null,"abstract":"For the month of February 2022, APBN looks at the many ways research is paving the way for improved cancer treatment outcomes. In Features, Kenneth Tan, President of Asia-Pacific, Japan and India at Varian, shares how we can accelerate the path from cancer diagnosis to therapy, improving survivorship. Then, Lance Kawaguchi, CEO of Cure Brain Cancer Foundation, writes about the importance of cancer research, its challenges, and how the Foundation is working to support brain cancer research. For our last feature, we have Dr Ahmed Abdelal, Global Head Medical Affairs Interventional Imaging and North America Head of Medical & Regulatory Affairs, Guerbet and Dr Binta Patel, North America Medical Affairs Manager, Guerbet, to give us a treatment update for hepatocellular carcinoma. Other topics covered in this issue includes the importance of trust in the pharmaceutical industry and how companies can improve trust with technology-led transparency, how we may learn from the pandemic and better prepare for the next unknown crisis, a discussion on the incidence of Omicron and Delta variants in two case studies, and an interview with a spokesperson from Novartis on their newly approved cholesterol drug.","PeriodicalId":89742,"journal":{"name":"Asia-Pacific biotech news","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48595009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discoveries and Innovations in Drug Development (Vol. 26, No. 1, Full Issue) 药物开发中的发现与创新(第26卷第1期)

Asia-Pacific biotech news

Pub Date : 2021-12-28 DOI: 10.1142/s0219030322000015

For the month of January 2022, APBN looks at some discoveries and innovation in pharmacology. In Features, Dr Harish Dave, Co-Founder and Chief Medical Officer of AUM Biosciences, discusses today's shifting paradigm in oncology drug development towards highly selective, minimally toxic, and patient-centric treatments, while Jade Pallett, Chief Technology Officer for Zoono UK & Europe, sheds light on how antimicrobial coatings outdo traditional methods of disinfection. Then, we have A/Prof Alexandra Sharland, Dr Nicole Mifsud, and Eric Son to elucidate how understanding antigen-specificity of host T cells can reduce organ transplantation rejection. Finally, in Spotlights, we have two interviews – one where we speak to Mr Willson Deng, CEO of Arcstone, on the role of digital technology in supporting MedTech manufacturing, and the other with Liu Qun, Head of IQVIA, China, where we learn more about the Chinese biopharmaceutical market.

2022年1月，APBN关注药理学的一些发现和创新。在Features中，AUM Biosciences联合创始人兼首席医疗官Harish Dave博士讨论了当今肿瘤学药物开发的范式向高选择性、低毒性和以患者为中心的治疗转变，而Zoono UK&Europe首席技术官Jade Pallett则阐明了抗菌涂层如何超越传统消毒方法。然后，我们请Alexandra Sharland教授、Nicole Mifsud博士和Eric Son来阐明了解宿主T细胞的抗原特异性如何减少器官移植排斥反应。最后，在Spotlights，我们进行了两次采访——一次是与Arcstone首席执行官Willson Deng先生就数字技术在支持MedTech制造中的作用进行了交谈，另一次是采访了IQVIA中国区负责人刘群，在那里我们了解了更多关于中国生物制药市场的信息。

引用次数: 0

Future of Us – Transforming Healthcare With Intelligent Machines (Vol. 25, No. 12, Full Issue) 我们的未来-用智能机器改变医疗保健(第25卷，第12期，全期)

Asia-Pacific biotech news

Pub Date : 2021-12-01 DOI: 10.1142/s0219030321000124

For the month of December 2021, APBN looks the applications of artificial intelligence and robotics in the healthcare space. In Features, we hear from Christopher Khang, President and CEO of GE Healthcare ASEAN, on how innovative technologies such as AI and automation are shaping a bright future for radiologists and their patients. Then, we have David Irecki from Boomi, who proposes that a unified view of patient data can enable holistic, coordinated services that will improve people'soverall quality of life, and an article contribution by Lewis Ho, Chief Executive Officer at Avalon SteriTech on innovative healthcare solutions and the future of smart cleaning. Shifting away from intelligent machines, we speak to Dr. Goh Choo Beng, Head of Medical Affairs at Takeda APAC, on unmet disease areas and learn more about the different treatments and trials currently in the pipeline at Takeda, and finally, we wrap up the year 2021 with Lu-Ching Lau, Director for External Affairs, Policy and Communications, Singapore and Malaysia, MSD, as she shares with us how we may navigate through current and future health challenges.

2021年12月，APBN关注人工智能和机器人在医疗保健领域的应用。在Features中，我们听取了GE Healthcare ASEAN总裁兼首席执行官Christopher Khang关于人工智能和自动化等创新技术如何为放射科医生及其患者塑造光明未来的演讲。然后，我们有来自Boomi的David Irecki，他提出，患者数据的统一视图可以实现整体、协调的服务，从而提高人们的整体生活质量，以及Avalon SteriTech首席执行官Lewis Ho关于创新医疗解决方案和智能清洁未来的文章。从智能机器转向智能机器，我们与武田亚太地区医疗事务主管Goh Choo Beng博士就未满足的疾病领域进行了交谈，并了解了武田目前正在进行的不同治疗和试验的更多信息。最后，我们与默沙东新加坡和马来西亚外交、政策和沟通总监Lu Ching Lau一起结束了2021年，她与我们分享了我们如何应对当前和未来的健康挑战。

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Asia-Pacific biotech news

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀